Developer docs
API playgroundTry for free, no card

Search company profiles

NeuroRPM

Full company profile

uuid02kbdgs

Namestring
NeuroRPM
Legal namestring
NeuroRPM Inc.
Websiteurl
neurorpm.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

NeuroRPM is a Washington, D.C.-based digital health company founded in 2017 that develops FDA-cleared, AI-enabled remote monitoring technology for people living with neurodegenerative diseases, with a primary focus on Parkinson's disease. The company operates two product lines from a common sensor-and-algorithm platform: NeuroRPM-Rx, a prescription-based remote therapeutic monitoring (RPM) device delivered through neurology practices via the standard Apple Watch form factor, and NeuroRPM-CT, a clinical-trials platform that supplies continuous objective outcome measures to pharmaceutical and medical-device sponsors. The underlying technology uses proprietary algorithms to detect and quantify motor symptoms — including bradykinesia, tremor, and dyskinesia — from passively collected Apple Watch sensor data, and the platform is HIPAA-compliant with integrations into third-party health-data systems.

The product surface extends beyond core symptom tracking to include Companion Mode for caregiver data sharing, support for deep brain stimulation (DBS) programming workflows, and tools that surface longitudinal trends to clinicians, patients, and caregivers. NeuroRPM is a small private company (11–50 employees) operating exclusively in the U.S. market under FDA oversight, with its technology stack tightly coupled to Apple's hardware and software ecosystem.

NeuroRPM's business model combines recurring subscription-based remote physiological monitoring revenue from clinical care — distributed through physician prescription into neurology practices — with services revenue from clinical-trial sponsors running Parkinson's studies. Its go-to-market is effectively B2B2C: prescriptions originate from neurologists, while clinical-trial contracts are sourced directly from pharma and device sponsors, giving the company two distinct but complementary commercialization paths for the same underlying measurement technology.

Short descriptiontext

NeuroRPM is a Washington, D.C.-based digital health company building FDA-cleared, AI-enabled remote monitoring on Apple Watch for Parkinson's patients, serving neurology practices via prescription RPM and pharmaceutical sponsors through clinical trial outcome measures.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWashington, United States
HQ citystring
Washington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
remote patient monitoring, Parkinson's disease monitoring, digital health platform, wearable motor symptom tracking, clinical trial technology
Industry4 codes
PRIMARYHLALAFAJ
Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAGAC
Neurology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAKAIAC
Movement Disorders (Parkinson’s, Tremor, Dystonia)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Remote Patient Monitoring Software
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1NeuroRPM-Rx Subscription
TypeSubscription Recurring
Description

Physician-prescribed remote patient monitoring subscription service for Parkinson's care. The platform supports RPM billing and reimbursement workflows for practices, indicating recurring revenue through healthcare provider prescriptions.

neurorpm.com
2NeuroRPM-CT Clinical Trial Services
TypeProfessional Services
Description

Clinical trial monitoring services for pharmaceutical, medical device, and research partners providing objective symptom data and digital biomarkers for therapy development.

neurorpm.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

NeuroRPM develops an FDA-cleared, AI-enabled remote patient monitoring platform that uses Apple Watch sensors and a mobile application to detect and quantify Parkinson's motor symptoms (bradykinesia, tremor, dyskinesia). The company sells two product lines: NeuroRPM-Rx, a physician-prescribed subscription for clinical care, and NeuroRPM-CT, a clinical trial monitoring service for pharmaceutical and research partners. Both offerings include medication tracking, longitudinal symptom analytics, and HIPAA-compliant data handling.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 6.5% increase in ON Time, 5.0% reduction in Tremor Detected, 3.5% reduction in Bradykinesia Detected, 1.0% reduction in Dyskinesia Detected following medication timing adjustment
+1 more record
Product overview1 text field

NeuroRPM offers two primary product lines: NeuroRPM-Rx for clinical care and NeuroRPM-CT for clinical trials. NeuroRPM-Rx is an FDA-cleared, AI-enabled, physician-prescribed remote patient monitoring platform that uses Apple Watch, mobile software, and advanced analytics to monitor Parkinson's motor symptoms while supporting medication tracking and clinical care decisions. NeuroRPM-CT serves pharmaceutical, medical device, and research partners with objective symptom monitoring for therapy development. Both products are supported by a mobile application featuring a Companion Mode for data sharing with caregivers, and built-in RPM workflows for reimbursement support.

Product and service3 records
1NeuroRPM-Rx
CategoryRemote Patient Monitoring Platform
Description

AI-enabled, physician-prescribed remote patient monitoring platform for Parkinson's disease clinical care. Uses Apple Watch, mobile software, and advanced analytics to detect and visualize bradykinesia, tremor, and dyskinesia, while supporting medication tracking and integration of supplemental health data. Designed for neurology practices treating Parkinson's patients.

2NeuroRPM-CT
CategoryClinical Trial Monitoring Platform
Description

Clinical trial support platform designed for pharmaceutical, medical device, and research partners. Provides objective Parkinson's motor symptom monitoring, medication context, baseline and longitudinal tracking, and real-world data to complement traditional clinical trial assessments for therapy development programs.

3NeuroRPM Mobile Application
CategoryMobile Health Application
Description

Companion iOS and Android mobile application that captures, uploads, transmits, displays, and accesses movement, health, and wellness information for individuals being evaluated for or diagnosed with Parkinson's disease, integrating with Apple Health and Google Fit.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or Integration
Description

NeuroRPM uses Apple Watch as the primary sensing device for collecting movement and motion data to monitor Parkinson's motor symptoms. The platform integrates with Apple Health data including heart rate, sleep, physical activity, and other health metrics collected by Apple Watch.

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Maker of FDA-cleared wearable sensors (EpiMonitor) and AI analytics for continuous neurological monitoring, with FDA-cleared SaMD pathways overlapping NeuroRPM's regulatory and product positioning in neurology RPM.

TypeDirect peer
Description

Developer of Kinesia and Kinesia One wearable systems for objective measurement of Parkinson's motor symptoms (tremor, bradykinesia, dyskinesia), directly competing with NeuroRPM in clinical-care and clinical-trial Parkinson's monitoring.

TypeDirect peer
Description

Developer of Cala Trio, a wearable neuromodulation device for essential tremor and Parkinson's tremor therapy, with overlap in Parkinson's wearable monitoring and clinical-trial digital biomarker collaborations.

TypeOthers
Description

Non-profit running the Parkinson's mPower study on iPhone/Apple Watch, overlapping with NeuroRPM's use of Apple Watch for Parkinson's data collection and shaping industry expectations for digital Parkinson biomarkers.

TypeDirect peer
Description

Rune Labs' Strive PD platform uses Apple Watch and wearable sensors to monitor Parkinson's motor symptoms and provides digital biomarkers to pharma for clinical trials—the closest direct competitor to NeuroRPM-Rx and NeuroRPM-CT, including a partnership with Roche.

TypeBroad incumbent
Description

Alphabet's health-technology subsidiary developing wearable and sensor-based digital biomarkers (historically including Parkinson's research with the Sync Project), operating as a larger incumbent in wearable-driven neurological monitoring.

7Biofourmis
TypeDirect peer
Description

AI-driven remote patient monitoring and digital therapeutics platform with neurology and chronic-disease RPM offerings, competing with NeuroRPM in physician-prescribed RPM reimbursement workflows and pharma-grade digital endpoints.

TypeOthers
Description

Marketer of Parkinson's therapies (e.g., Duopa, Vyalev) and a potential NeuroRPM-CT enterprise customer/partner for objective digital endpoints in Parkinson's drug development trials.

TypeBroad incumbent
Description

Manufacturer of Activa deep brain stimulation (DBS) systems for Parkinson's, with adjacent digital health efforts to objectively measure DBS outcomes—a clinical workflow that NeuroRPM specifically targets with its DBS programming evaluation feature.

TypeDirect peer
Description

Australian-based company behind the PKG (Personal KinetiGraph) wearable for continuous Parkinson's motor symptom monitoring, providing both clinical care and pharma-trial digital endpoints in the same category as NeuroRPM.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuroRPM

Remote Patient Monitoring Softwareneurorpm.com

NeuroRPM is a Washington, D.C.-based digital health company building FDA-cleared, AI-enabled remote monitoring on Apple Watch for Parkinson's patients, serving neurology practices via prescription RPM and pharmaceutical sponsors through clinical trial outcome measures.

What NeuroRPM does

NeuroRPM is a Washington, D.C.-based digital health company founded in 2017 that develops FDA-cleared, AI-enabled remote monitoring technology for people living with neurodegenerative diseases, with a primary focus on Parkinson's disease. The company operates two product lines from a common sensor-and-algorithm platform: NeuroRPM-Rx, a prescription-based remote therapeutic monitoring (RPM) device delivered through neurology practices via the standard Apple Watch form factor, and NeuroRPM-CT, a clinical-trials platform that supplies continuous objective outcome measures to pharmaceutical and medical-device sponsors. The underlying technology uses proprietary algorithms to detect and quantify motor symptoms — including bradykinesia, tremor, and dyskinesia — from passively collected Apple Watch sensor data, and the platform is HIPAA-compliant with integrations into third-party health-data systems.

The product surface extends beyond core symptom tracking to include Companion Mode for caregiver data sharing, support for deep brain stimulation (DBS) programming workflows, and tools that surface longitudinal trends to clinicians, patients, and caregivers. NeuroRPM is a small private company (11–50 employees) operating exclusively in the U.S. market under FDA oversight, with its technology stack tightly coupled to Apple's hardware and software ecosystem.

NeuroRPM's business model combines recurring subscription-based remote physiological monitoring revenue from clinical care — distributed through physician prescription into neurology practices — with services revenue from clinical-trial sponsors running Parkinson's studies. Its go-to-market is effectively B2B2C: prescriptions originate from neurologists, while clinical-trial contracts are sourced directly from pharma and device sponsors, giving the company two distinct but complementary commercialization paths for the same underlying measurement technology.

NeuroRPM firmographics

Firmographics
Name
NeuroRPM
Legal name
NeuroRPM Inc.
Website
https://neurorpm.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
NeuroRPM is a Washington, D.C.-based digital health company building FDA-cleared, AI-enabled remote monitoring on Apple Watch for Parkinson's patients, serving neurology practices via prescription RPM and pharmaceutical sponsors through clinical trial outcome measures.
Ownership category
akta.pro rank

NeuroRPM industry classification

Industry
Product category
Remote Patient Monitoring Software
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLALAFAJ
Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAGAC
Neurology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAKAIAC
Movement Disorders (Parkinson’s, Tremor, Dystonia)

Keywords

  • Remote patient monitoring
  • Parkinson's disease monitoring
  • Digital health platform
  • Wearable motor symptom tracking
  • Clinical trial technology

Where NeuroRPM is headquartered

Location

Headquarters

HQ city
Washington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NeuroRPM business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

  1. NeuroRPM-Rx Subscription: Physician-prescribed remote patient monitoring subscription service for Parkinson's care. The platform supports RPM billing and reimbursement workflows for practices, indicating recurring revenue through healthcare provider prescriptions.
  2. NeuroRPM-CT Clinical Trial Services: Clinical trial monitoring services for pharmaceutical, medical device, and research partners providing objective symptom data and digital biomarkers for therapy development.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

NeuroRPM product offering

Product offering

Core offering

NeuroRPM develops an FDA-cleared, AI-enabled remote patient monitoring platform that uses Apple Watch sensors and a mobile application to detect and quantify Parkinson's motor symptoms (bradykinesia, tremor, dyskinesia). The company sells two product lines: NeuroRPM-Rx, a physician-prescribed subscription for clinical care, and NeuroRPM-CT, a clinical trial monitoring service for pharmaceutical and research partners. Both offerings include medication tracking, longitudinal symptom analytics, and HIPAA-compliant data handling.

Product overview

NeuroRPM offers two primary product lines: NeuroRPM-Rx for clinical care and NeuroRPM-CT for clinical trials. NeuroRPM-Rx is an FDA-cleared, AI-enabled, physician-prescribed remote patient monitoring platform that uses Apple Watch, mobile software, and advanced analytics to monitor Parkinson's motor symptoms while supporting medication tracking and clinical care decisions. NeuroRPM-CT serves pharmaceutical, medical device, and research partners with objective symptom monitoring for therapy development. Both products are supported by a mobile application featuring a Companion Mode for data sharing with caregivers, and built-in RPM workflows for reimbursement support.

Differentiator

Problem solved

Functional benefit

Products and services

  • NeuroRPM-Rx AI-enabled, physician-prescribed remote patient monitoring platform for Parkinson's disease clinical care. Uses Apple Watch, mobile software, and advanced analytics to detect and visualize bradykinesia, tremor, and dyskinesia, while supporting medication tracking and integration of supplemental health data. Designed for neurology practices treating Parkinson's patients.
  • NeuroRPM-CT Clinical trial support platform designed for pharmaceutical, medical device, and research partners. Provides objective Parkinson's motor symptom monitoring, medication context, baseline and longitudinal tracking, and real-world data to complement traditional clinical trial assessments for therapy development programs.
  • NeuroRPM Mobile Application Companion iOS and Android mobile application that captures, uploads, transmits, displays, and accesses movement, health, and wellness information for individuals being evaluated for or diagnosed with Parkinson's disease, integrating with Apple Health and Google Fit.

Quantifiable outcome

  • 6.5% increase in ON Time, 5.0% reduction in Tremor Detected, 3.5% reduction in Bradykinesia Detected, 1.0% reduction in Dyskinesia Detected following medication timing adjustment
  • +1 more outcomes

Companies that use NeuroRPM

Customer profile

Segments2 records

Ideal customer profiles2 records

NeuroRPM technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability4 records

Feature5 records

NeuroRPM partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ApplecoreTechnology or IntegrationNeuroRPM uses Apple Watch as the primary sensing device for collecting movement and motion data to monitor Parkinson's motor symptoms. The platform integrates with Apple Health data including heart rate, sleep, physical activity, and other health metrics collected by Apple Watch.

Scale indicators1 record

Expansion highlights5 records

NeuroRPM competitors and assessment

Company assessment

Direct peers

  • Empatica: Maker of FDA-cleared wearable sensors (EpiMonitor) and AI analytics for continuous neurological monitoring, with FDA-cleared SaMD pathways overlapping NeuroRPM's regulatory and product positioning in neurology RPM.
  • Great Lakes NeuroTechnologies: Developer of Kinesia and Kinesia One wearable systems for objective measurement of Parkinson's motor symptoms (tremor, bradykinesia, dyskinesia), directly competing with NeuroRPM in clinical-care and clinical-trial Parkinson's monitoring.
  • Cala Health: Developer of Cala Trio, a wearable neuromodulation device for essential tremor and Parkinson's tremor therapy, with overlap in Parkinson's wearable monitoring and clinical-trial digital biomarker collaborations.
  • Rune Labs: Rune Labs' Strive PD platform uses Apple Watch and wearable sensors to monitor Parkinson's motor symptoms and provides digital biomarkers to pharma for clinical trials—the closest direct competitor to NeuroRPM-Rx and NeuroRPM-CT, including a partnership with Roche.
  • Biofourmis: AI-driven remote patient monitoring and digital therapeutics platform with neurology and chronic-disease RPM offerings, competing with NeuroRPM in physician-prescribed RPM reimbursement workflows and pharma-grade digital endpoints.
  • Global Kinetics: Australian-based company behind the PKG (Personal KinetiGraph) wearable for continuous Parkinson's motor symptom monitoring, providing both clinical care and pharma-trial digital endpoints in the same category as NeuroRPM.

Others

  • Sage Bionetworks: Non-profit running the Parkinson's mPower study on iPhone/Apple Watch, overlapping with NeuroRPM's use of Apple Watch for Parkinson's data collection and shaping industry expectations for digital Parkinson biomarkers.
  • AbbVie: Marketer of Parkinson's therapies (e.g., Duopa, Vyalev) and a potential NeuroRPM-CT enterprise customer/partner for objective digital endpoints in Parkinson's drug development trials.

Broad incumbents

  • Verily (Alphabet): Alphabet's health-technology subsidiary developing wearable and sensor-based digital biomarkers (historically including Parkinson's research with the Sync Project), operating as a larger incumbent in wearable-driven neurological monitoring.
  • Medtronic: Manufacturer of Activa deep brain stimulation (DBS) systems for Parkinson's, with adjacent digital health efforts to objectively measure DBS outcomes—a clinical workflow that NeuroRPM specifically targets with its DBS programming evaluation feature.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

NeuroRPM social profiles

Digital presence

NeuroRPM compliance and trust

Trust signal

Compliance2 records

NeuroRPM financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuroRPM leadership team

Management profile

Number of profiles

Profiles9 records

NeuroRPM funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuroRPM M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroRPM

What does NeuroRPM do?

NeuroRPM develops an FDA-cleared, AI-enabled remote patient monitoring platform that uses Apple Watch sensors and a mobile application to detect and quantify Parkinson's motor symptoms (bradykinesia, tremor, dyskinesia). The company sells two product lines: NeuroRPM-Rx, a physician-prescribed subscription for clinical care, and NeuroRPM-CT, a clinical trial monitoring service for pharmaceutical and research partners. Both offerings include medication tracking, longitudinal symptom analytics, and HIPAA-compliant data handling.

Is NeuroRPM a public or private company?

NeuroRPM is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NeuroRPM founded?

NeuroRPM was founded in 2017. It employs 11 to 50 people.

Where is NeuroRPM based?

NeuroRPM is headquartered in Washington, United States, in the North America region.

How does NeuroRPM make money?

Two revenue lines are on record. NeuroRPM-Rx Subscription is the primary driver. The others are neuroRPM-CT Clinical Trial Services.

Who are NeuroRPM's main competitors?

Direct peers on record are Empatica, Great Lakes NeuroTechnologies, Cala Health, Rune Labs, Biofourmis and Global Kinetics. Others are Sage Bionetworks and AbbVie. Broad incumbents are Verily (Alphabet) and Medtronic.

Does NeuroRPM have an API?

No public API is recorded for NeuroRPM.

What industry is NeuroRPM in?

NeuroRPM's product category is Remote Patient Monitoring Software. Its primary akta.pro industry code is HLALAFAJ, Neurology RPM (epilepsy, Parkinson’s, MS monitoring), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comAnnovis Bio receives patent for buntanetap in brain infections By Investing.comAnnovis Bio Inc. announced the issuance of U.S. Patent No. 12,582,632 B2 covering the prevention and treatment of neurological injuries from brain infections using buntanetap or related compounds, including infections from herpes simplex virus, HIV, COVID, Lyme disease bacteria, and periodontal disease bacteria. The patent extends intellectual property protection for buntanetap through 2044 and includes claims for both preventive use in at-risk individuals and reversal of existing neurological damage. The company, a Phase 3 clinical-stage biotechnology firm, is also advancing buntanetap for neurodegenerative diseases including Alzheimer's and Parkinson's disease, with recent developments including a CFO transition and a partnership with NeuroRPM for AI-powered clinical trial monitoring.GlobeNewswireNeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical TrialNeuroRPM announced its FDA-cleared wearable platform will monitor Parkinson's symptoms in Annovis Bio's ANVS-25002 trial, which enrolls about 500 participants. The Apple Watch-based device passively collects movement data to measure bradykinesia, tremor, and dyskinesia in real-world settings.MobiHealthNewsNeuroRPM obtains FDA 510(k) for Parkinson's monitoring on Apple WatchNeuroRPM received FDA 510(k) clearance for its AI-enabled app that uses an Apple Watch to track Parkinson's symptoms like bradykinesia, tremor, and dyskinesia. The company's algorithms continuously scan the wearable's data to monitor these symptoms and related health metrics.Business Wire BlogNeuroRPM Inc. Announces FDA Clearance for NeuroRPM, the AI-Powered Remote Monitoring App for Parkinson’s Disease on Apple WatchNeuroRPM Inc. received FDA clearance for its NeuroRPM app, which uses AI and Apple Watch to passively monitor Parkinson's disease symptoms. The app assesses bradykinesia, tremor, and dyskinesia with accuracy comparable to a neurologist. It is available by prescription and uses only data users share.Business Wire BlogNeuroRPM Inc. Announces FDA Clearance for NeuroRPM, the AI-Powered Remote Monitoring App for Parkinson’s Disease on Apple WatchNeuroRPM Inc. received FDA clearance for its NeuroRPM app, which uses AI and Apple Watch to passively monitor Parkinson's disease symptoms. The app assesses bradykinesia, tremor, and dyskinesia with accuracy comparable to a neurologist. It is available by prescription and uses only data users share.